Trial Profile
A Double-Blind, Randomized Study of Clopidogrel 75 mg/d vs Placebo, on a Background of ASA 75-100 mg/d, in Peripheral Arterial Disease (PAD) Patients Receiving a Unilateral Below Knee Bypass Graft
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary)
- Indications Embolism and thrombosis; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms CASPAR
- Sponsors Sanofi
- 30 Nov 2006 Status change
- 07 Aug 2006 Status change
- 26 Nov 2005 New trial record.